HDAC2 is a poor prognostic factor in patients receiving anthracycline therapy and is positively correlated with breast cancer metastasis, progression, increased Ki-67, multidrug resistance protein, and negatively correlated with overall survival of patients [44]. The gene discussed is HDAC2; the disease is breast cancer.